Nitric Oxide in Hematological Cancers: Partner or Rival?

被引:13
|
作者
Vivarelli, Silvia [1 ]
Falzone, Luca [1 ,2 ]
Basile, Maria Sofia [1 ]
Candido, Saverio [1 ,3 ]
Libra, Massimo [1 ,3 ]
机构
[1] Univ Catania, Dept Biomed & Biotechnol Sci, Via Santa Sofia 97, I-95123 Catania, Italy
[2] IRCCS Ist Nazl Tumori Fdn G Pascale, Epidemiol Unit, Naples, Italy
[3] Univ Catania, Res Ctr Prevent Diag & Treatment Canc, Catania, Italy
关键词
nitric oxide; nitric oxide synthase; leukemia; lymphoma; myeloma; combination therapy; CELL LUNG-CANCER; SIGNAL-REGULATED KINASE; PARTIAL-RESPONSE; IN-VITRO; MOLECULAR-MECHANISMS; GUANYLATE-CYCLASE; INDUCED APOPTOSIS; DRUG-RESISTANCE; LEUKEMIA-CELLS; SMOOTH-MUSCLE;
D O I
10.1089/ars.2019.7958
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent Advances: It is becoming progressively clear that NO modulation may help hematological cancer management, either by targeting directly tumor cells or by driving the immune system to eliminate cancer cells. Critical Issues: NO is a dual molecule that can have a tumor-protecting or stimulating effect, depending on its local concentration. Moreover, NO is able to target a wide range of molecules involved in both cancer genesis and evolution. In this review, an overview of the recent findings regarding the pivotal role played by NO and nitric oxide synthase in cancer progression and anticancer therapy is presented, with particular focus on hematological malignancies. Future Directions: It is critical to establish the cancer-specific function of NO and critically drive its modulation to improve cancer management toward a personalized approach. This has a special importance in hematological tumors, where the urgency of finding eradicative therapies is constant.
引用
收藏
页码:383 / 401
页数:19
相关论文
共 50 条
  • [41] Measurable Residual Disease in Hematological Cancers
    Jamroziak, Krzysztof
    Pula, Bartosz
    CANCERS, 2024, 16 (22)
  • [42] RHOA Therapeutic Targeting in Hematological Cancers
    Santos, Juliana Carvalho
    Profitos-Peleja, Nuria
    Sanchez-Vinces, Salvador
    Roue, Gael
    CELLS, 2023, 12 (03)
  • [43] New strategies to hit hematological cancers
    Barreca, Marilia
    Bertoni, Francesco
    Barraja, Paola
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 270
  • [44] AGAP1, a novel binding partner of nitric oxide-sensitive guanylyl cyclase
    Meurer, S
    Pioch, S
    Wagner, K
    Müller-Esterl, W
    Gross, S
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) : 49346 - 49354
  • [45] Venous Thromboembolism (VTE) in Hematological and Non-Hematological Cancers: A Nationwide Analysis
    Rai, Manoj P.
    Bedi, Prabhjot Singh
    Kaner, Justin D.
    Kandola, Samanjit Kaur
    Norgais, Konchok
    Tageja, Nishant
    Laird-Fick, Heather
    Bussel, James B.
    Marksand, Stanley M.
    Abougergi, Marwan S.
    BLOOD, 2018, 132
  • [46] MULTIPLE PRIMARY CANCERS ASSOCIATED WITH HEMATOLOGICAL MALIGNANCIES
    NAGURA, EI
    KAWASHIMA, K
    YAMADA, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1985, 15 : 211 - 222
  • [47] Lipid changes occuring in the course of hematological cancers
    Małgorzata Kuliszkiewicz-Janus
    Rafał Małecki
    Abdulrahman Saeed Mohamed
    Cellular & Molecular Biology Letters, 2008, 13
  • [48] Lipid changes occuring in the course of hematological cancers
    Kuliszkiewicz-Janus, Malgorzata
    Malecki, Rafal
    Mohamed, Abdulrahman Saeed
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2008, 13 (03) : 465 - 474
  • [49] Telomerase regulation in hematological cancers: A matter of stemness?
    Deville, Laure
    Hillion, Josette
    Segal-Bendirdjian, Evelyne
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2009, 1792 (04): : 229 - 239
  • [50] Hedgehog signaling inhibitors in solid and hematological cancers
    Cortes, Jorge E.
    Gutzmer, Ralf
    Kieran, Mark W.
    Solomon, James A.
    CANCER TREATMENT REVIEWS, 2019, 76 : 41 - 50